secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-06-10T20:15:16+00:00
Accession:  0001193125-26-265852
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax shareholders approve 2026 equity plans; 7.2M new shares reserved
-----------------------------------------------------------------------

- Stockholders approved 2026 Equity Incentive Plan authorizing 7,200,000 new shares plus returning shares from prior plan.
- Stockholders also approved 2026 Employee Stock Purchase Plan as successor to 2015 ESPP; no rollover of prior shares.
- Proposal 4 (2026 Plan) passed with 33,333,263 for vs. 25,392,051 against; Proposal 5 (ESPP) passed with 58,661,941 for.
- All director nominees elected and advisory vote on executive compensation passed; ratification of auditor approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/0001193125-26-265852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/sndx-20260610.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-265852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer